BIOA three-lens brief
Evidence-based stock research on BIOA. Three independent lenses — Foundation, Expansion, Climate — examine live data from SEC filings, the Federal Reserve, and market feeds. Every claim traces to its primary source.
Performance
50-day MA below 200-day MA (death-cross regime); price below both. · Trading at 5% of its 52-week range — deep in the lower band.
- Trading at 5% of its 52-week range — deep in the lower band.
- 50-day MA below 200-day MA (death-cross regime); price below both.
- Underperforming SPY by 16.8pp over 30 days.
- Currently unprofitable on a trailing basis — no P/E multiple available.
- Negative free cash flow last quarterly (-$67.58M).
BIOA closed at $5.87 (+1.56%) as of 2026-11-12. Market cap: $269.73M. Price is below the 50-day MA and below the 200-day MA. Concerns: trading at 5% of its 52-week range — deep in the lower band.; 50-day MA below 200-day MA (death-cross regime); price below both.. Last quarter: Revenue $298.0K, net income -$33.50M, free cash flow -$67.58M.
Why three lenses on BIOA, not one.
A single reasoning model has blind spots it doesn’t know about. We examine BIOA across Foundation (fundamentals), Expansion (growth runway and market expansion), and Climate (macro/sector). Disagreement between lenses is surfaced, not hidden — it’s how you know when HOLD is the honest call.
Read the full methodologyDrop it in your newsletter or blog.
Free to embed. Updates every 6 hours. Links back to the full brief.
<iframe src="https://www.clearpathinvest.app/embed/BIOA" width="100%" height="420" frameborder="0" loading="lazy" title="ClearPath BIOA brief"></iframe>